For the primary endpoint of AGV at Week 52, children treated with TransCon CNP (n=57) demonstrated an LS mean AGV of 5.89 ...

In the trial, doses ranging from 0.5mg to 0.9mg of ALG-055009 led to notable median relative reductions in liver fat.

An NIH-supported clinical trial of pomalidomide in treating hereditary hemorrhagic telangiectasia stopped early due to ...

Insilico Medicine has announced positive preliminary results from its Phase IIa clinical trial of ISM001-055, a small ...

Suven Life Sciences' Ropanicant shows promise for MDD treatment, with positive Phase 2a results and plans for Phase 2b study.

Three months of supplementation with a prebiotic blend of inulin and oligofructose may significantly improve measures of ...

The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of ...

In a randomized double-blind placebo-controlled study, naldemedine use was associated with constipation prevention and a ...

The RESILIENCE clinical trial has been designed to explore the effectiveness and safety of remote ischemic conditioning (RIC) ...

SOLARIS (Alliance A021703), a multicenter, double-blind, randomized Phase III clinical trial led by Dana-Farber Cancer ...

An oral small molecule drug, SAT-3247 targets AAK1. It is created to promote skeletal muscle regeneration in DMD and similar ...

Researchers have recently reported improvement of vision in patients with keratoconus (KC) even if spectacle correction was ...